Core Viewpoint - The company is actively investing in health industry funds and enhancing its research and development efforts, indicating a long-term strategy for sustainable growth despite short-term performance fluctuations [1][6]. Group 1: Investment Activities - The company has invested 200 million yuan in the Gao Xin Run Xin health industry investment partnership, marking the completion of private fund registration [1]. - This investment is part of the "Yuan Shan Plan" initiated by Zhangzhou, under which the company has participated in three industry investment funds since April 2024 [2]. - The company aims to leverage these investments to build a comprehensive health industry ecosystem, including traditional Chinese medicine, biomedicine, medical devices, and personal care products [2]. Group 2: Research and Development - The company is focusing on R&D innovation in traditional Chinese medicine, with significant investments in modern medical research [3]. - The company announced the completion of Phase III clinical trials for its innovative traditional Chinese medicine, Wen Zhan Pian, targeting anxiety disorders, which reflects its commitment to addressing market needs [4]. - In the first half of 2025, the company is advancing 18 new drug research projects, including five traditional Chinese medicine innovations and several chemical drug trials [5]. Group 3: Market Position and Future Outlook - The company is responding to national policies promoting traditional Chinese medicine innovation, aiming to solidify its leading position in the industry [4]. - Despite short-term performance pressures, the company's strategic investments and R&D initiatives are expected to enhance its long-term competitiveness and contribute to the modernization of traditional Chinese medicine [6].